Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.

Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0435-7. [Epub ahead of print]

PMID:
30858549
2.

Natural history of multiple myeloma with de novo del(17p).

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2019 Mar 7;9(3):32. doi: 10.1038/s41408-019-0191-y.

3.

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.

Ramakrishnan VG, Miller KC, Macon EP, Kimlinger TK, Haug J, Kumar S, Gonsalves WI, Rajkumar SV, Kumar SK.

Haematologica. 2019 Mar 7. pii: haematol.2018.211110. doi: 10.3324/haematol.2018.211110. [Epub ahead of print]

4.

Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.

Sidana S, Tandon N, Gertz MA, Dispenzieri A, Ramirez-Alvarado M, Murray DL, Kourelis TV, Buadi FK, Kapoor P, Gonsalves W, Warsame R, Lacy MQ, Kyle RA, Rajkumar SV, Kumar SK, Leung N.

Br J Haematol. 2019 Mar 5. doi: 10.1111/bjh.15832. [Epub ahead of print]

PMID:
30836444
5.

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma.

Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Dispenzieri A, Kourelis TV, Warsame R, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Hwa YL, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Kumar SK.

Blood Adv. 2019 Mar 12;3(5):744-750. doi: 10.1182/bloodadvances.2018022806.

6.

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.

Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, Kumar SK.

Leukemia. 2019 Feb 20. doi: 10.1038/s41375-019-0419-7. [Epub ahead of print]

PMID:
30787429
7.

A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.

Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, Kumar SK, Dispenzieri A.

Mayo Clin Proc. 2019 Mar;94(3):472-483. doi: 10.1016/j.mayocp.2018.08.006. Epub 2019 Feb 13.

PMID:
30770096
8.

Substratification of patients with newly diagnosed standard-risk multiple myeloma.

Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK.

Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15800. [Epub ahead of print]

PMID:
30768679
9.

Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.

Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A.

Leukemia. 2019 Feb 8. doi: 10.1038/s41375-019-0400-5. [Epub ahead of print]

PMID:
30737485
10.

Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis.

Sidana S, Tandon N, Brady PA, Grogan M, Gertz MA, Dispenzieri A, Lin G, Dingli D, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Muchtar E, Warsame R, Kumar SK, Kourelis TV.

Mayo Clin Proc. 2019 Mar;94(3):455-464. doi: 10.1016/j.mayocp.2018.08.039. Epub 2019 Feb 2.

PMID:
30718070
11.

The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?

Müller AMS, Kumar SK, Bruno B.

Haematologica. 2019 Feb;104(2):222-225. doi: 10.3324/haematol.2018.206987. No abstract available.

12.

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG.

Leukemia. 2019 Jan 29. doi: 10.1038/s41375-019-0384-1. [Epub ahead of print]

PMID:
30696949
13.

Targeted Management Strategies in Multiple Myeloma.

Kumar SK.

Cancer J. 2019 Jan/Feb;25(1):59-64. doi: 10.1097/PPO.0000000000000353.

PMID:
30694861
14.

Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.

Sidana S, Jevremovic D, Ketterling RP, Tandon N, Greipp PT, Baughn LB, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 Jan 25. doi: 10.1002/ajh.25420. [Epub ahead of print] No abstract available.

PMID:
30680770
15.

Comparative analysis of staging systems in AL amyloidosis.

Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Leukemia. 2019 Mar;33(3):811-814. doi: 10.1038/s41375-018-0370-z. Epub 2019 Jan 23. No abstract available.

PMID:
30675009
16.

Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method.

Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 Apr;94(4):424-430. doi: 10.1002/ajh.25391. Epub 2019 Jan 8.

PMID:
30592078
17.

Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.

Kumar SK, Buadi FK, Rajkumar SV.

Blood. 2019 Feb 14;133(7):652-659. doi: 10.1182/blood-2018-08-825349. Epub 2018 Dec 26. Review.

PMID:
30587528
18.

Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay.

Muchtar E, Kumar SK, Gertz MA, Grogan M, AbouEzzeddine OF, Jaffe AS, Dispenzieri A.

Blood. 2019 Feb 14;133(7):763-766. doi: 10.1182/blood-2018-10-875252. Epub 2018 Dec 13. No abstract available.

PMID:
30545829
19.

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.

Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV.

Blood Cancer J. 2018 Dec 11;8(12):125. doi: 10.1038/s41408-018-0163-7.

20.

Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.

Sidiqi MH, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA.

Biol Blood Marrow Transplant. 2018 Dec 7. pii: S1083-8791(18)30802-4. doi: 10.1016/j.bbmt.2018.12.003. [Epub ahead of print]

PMID:
30529461
21.

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma.

Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK.

Am J Hematol. 2019 Mar;94(3):306-311. doi: 10.1002/ajh.25365. Epub 2018 Dec 13.

PMID:
30516847
22.

Should we measure clonal circulating plasma cells in light chain amyloidosis?

Sidana S, Kumar SK, Gonsalves WI.

Oncotarget. 2018 Nov 2;9(86):35607-35608. doi: 10.18632/oncotarget.26289. eCollection 2018 Nov 2. No abstract available.

23.

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.

Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2018 Nov 27;2(22):3149-3154. doi: 10.1182/bloodadvances.2018024794.

24.

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Kumar SK, Grzasko N, Delimpasi S, Jedrzejczak WW, Grosicki S, Kyrtsonis MC, Spencer A, Gupta N, Teng Z, Byrne C, Labotka R, Dimopoulos MA.

Br J Haematol. 2019 Feb;184(4):536-546. doi: 10.1111/bjh.15679. Epub 2018 Nov 20.

PMID:
30460684
25.

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.

Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV.

Blood Cancer J. 2018 Nov 15;8(12):116. doi: 10.1038/s41408-018-0140-1.

26.

Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.

Kumar SK, Gertz MA, Dispenzieri A.

J Clin Oncol. 2019 Jan 10;37(2):171-173. doi: 10.1200/JCO.18.01398. Epub 2018 Nov 15. No abstract available.

PMID:
30433848
27.

Timing of treatment of smoldering myeloma: delay until progression.

Kumar SK.

Blood Adv. 2018 Nov 13;2(21):3050-3053. doi: 10.1182/bloodadvances.2018021238. No abstract available.

28.

Ixazomib for the treatment of multiple myeloma.

Richardson PG, Zweegman S, O'Donnell EK, Laubach JP, Raje N, Voorhees P, Ferrari RH, Skacel T, Kumar SK, Lonial S.

Expert Opin Pharmacother. 2018 Dec;19(17):1949-1968. doi: 10.1080/14656566.2018.1528229. Epub 2018 Nov 13. Review.

PMID:
30422008
29.

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC.

Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0. Review.

30.

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.

Sidiqi MH, Aljama MA, Bin Riaz I, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA.

Blood Cancer J. 2018 Nov 8;8(11):106. doi: 10.1038/s41408-018-0147-7.

31.

Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Wolf RC, Kumar SK, Gertz MA.

Bone Marrow Transplant. 2018 Nov 2. doi: 10.1038/s41409-018-0388-x. [Epub ahead of print]

PMID:
30390060
32.

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK.

Leukemia. 2019 Mar;33(3):730-738. doi: 10.1038/s41375-018-0271-1. Epub 2018 Oct 15.

PMID:
30323358
33.

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Leukemia. 2019 Feb;33(2):527-531. doi: 10.1038/s41375-018-0258-y. Epub 2018 Sep 26. No abstract available.

PMID:
30258095
34.

Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma.

Aljama MA, Sidiqi MH, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK.

Am J Hematol. 2018 Dec;93(12):1518-1523. doi: 10.1002/ajh.25279. Epub 2018 Oct 2.

PMID:
30194770
35.

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators.

N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.

36.

Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma.

Miller KC, Gertz MA, Buadi FK, Hayman SR, Wolf RC, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI, Kourelis T, Hogan WJ, Kumar SK.

Bone Marrow Transplant. 2018 Aug 16. doi: 10.1038/s41409-018-0302-6. [Epub ahead of print]

37.

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma.

Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ.

Blood Cancer J. 2018 Jul 30;8(8):70. doi: 10.1038/s41408-018-0106-3.

38.

Monoclonal Antibodies for Myeloma: Make It Easy!

Kumar SK.

J Oncol Pract. 2018 Jul;14(7):423-424. doi: 10.1200/JOP.18.00350. No abstract available.

PMID:
29996067
39.

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V.

Bone Marrow Transplant. 2018 Jul 9. doi: 10.1038/s41409-018-0264-8. [Epub ahead of print] Review.

PMID:
29988062
40.

Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2157-2159. doi: 10.1016/j.bbmt.2018.06.017. Epub 2018 Jun 20.

PMID:
29933071
41.

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4.

42.

Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'.

Lakshman A, Ravi P, Rajkumar SV, Kumar SK.

Leukemia. 2018 Sep;32(9):2083-2085. doi: 10.1038/s41375-018-0155-4. Epub 2018 May 25. No abstract available.

PMID:
29802327
43.

Management of Multiple Myeloma.

Kumar SK.

J Natl Compr Canc Netw. 2018 May;16(5S):624-627. doi: 10.6004/jnccn.2018.0040.

PMID:
29784741
44.

Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation.

Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA.

Br J Haematol. 2018 Jul;182(1):71-77. doi: 10.1111/bjh.15244. Epub 2018 Apr 29.

PMID:
29707759
45.

The multiple myelomas - current concepts in cytogenetic classification and therapy.

Kumar SK, Rajkumar SV.

Nat Rev Clin Oncol. 2018 Jul;15(7):409-421. doi: 10.1038/s41571-018-0018-y. Review.

PMID:
29686421
46.

Time to plateau as a predictor of survival in newly diagnosed multiple myeloma.

Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Vincent Rajkumar S, Kumar SK.

Am J Hematol. 2018 Jul;93(7):889-894. doi: 10.1002/ajh.25113.

PMID:
29659048
47.

Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.

Kansagra A, Gonsalves WI, Gertz MA, Buadi FK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Kapoor P, Muchtar E, Kourelis TV, Warsame R, Leung N, Zeldenrust SR, Lust JA, Rajkumar SV, Kyle RA, Hogan W, Kumar SK.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2127-2132. doi: 10.1016/j.bbmt.2018.04.007. Epub 2018 Apr 12.

PMID:
29656139
48.

Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma.

Chakraborty R, Hamilton BK, Hashmi SK, Kumar SK, Majhail NS.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1546-1553. doi: 10.1016/j.bbmt.2018.03.027. Epub 2018 Apr 4. Review.

PMID:
29626515
49.

Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kumar SK, Kapoor P, Kourelis TV, Hogan WJ, Gertz MA.

Blood Adv. 2018 Apr 10;2(7):769-776. doi: 10.1182/bloodadvances.2018016782.

50.

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Leukemia. 2018 Oct;32(10):2240-2249. doi: 10.1038/s41375-018-0060-x. Epub 2018 Feb 20.

PMID:
29581546

Supplemental Content

Loading ...
Support Center